Background Information: Currently alpha1-adrenoreceptor blockers with the combination of 5- alpha reductase inhibitors are widely used as first-line therapy to improve Lower urinary tract symptoms (LUTS) associated with Benign Prostatic Hyperplasia (BPH). Aims And Objectives:The aim of this study was to evaluate the Efficacy of combination drug Silodosin and Dutasteride in Benign Prostatic Hyperplasia patients with mild to severe symptoms. Materials And Methods:Thepresent hospital based Prospective Interventional Observational study was conducted in Department of Urology and Surgery out and inpatient Department,Lalitha Super Speciality Hospital during the time period of 1st October 2020 to 31st March 2021 and 70 cases of BPH with mild to severe symptoms and prostate volume of greater than30cc were included in the study All the patients were administered the drug which is a combination of Silodosin (8mg) and Dutasteride (0.5mg) once daily for 3 months after obtaining ethical clearance and administering informed consent .The patients condition was done followupfor the changes in Prostate Size,PVR,IPSS which were recorded and analysed using appropriate statistical tools. Results: The study showed that there was a significant decrease in prostate size when compared with before treatment i.e.11.31±5.99and a significant decrease in PostVoidResidual volume when compared with before treatment i.e 43.95±1.091.During therapy the IPSS score was improved to 9.5±1.567 which was found to be statistically significant (p<0.05).After 2 months of the treatment there was improvement in the patient condition ,as we saw the significant change in prostate size, post void residual volume and IPSS score after treatment.The patient with severe, moderateand mild benign prostate hyperplasia was improved by the treatment . Conclusion: There is statistically significant improvement in PVR ,IPSS and prostate size .Thus Silodosin 8mg and dutasteride 0.5mg can be used for effective relief of LUTS caused due to BPH in mild to severe cases.